Physician profile
Ebenezer Berko
NPI 1154366508
$1,108.80
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $114 · 2023: $67.71 · 2024: $33.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $101.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $170.14 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $159.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $133.94 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $127.12 | 2019 | |
| Astellas Pharma US INC | $99.95 | 2019 | |
| Amgen INC. | $56.92 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.55 | 2019 | |
| Tesaro, INC. | $37.49 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $36.66 | 2019-2020 | |
| Karyopharm Therapeutics INC. | $34.00 | 2023 | Xpovio |
| Pharmacosmos Therapeutics INC. | $33.34 | 2024 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $30.64 | 2019 | |
| Pfizer INC. | $28.49 | 2019 | |
| Stemline Therapeutics INC. | $20.25 | 2023 | Orserdu |
| Array Biopharma INC | $16.91 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eusa Pharma (US) LLC | $16.30 | 2019 | |
| Partner Therapeutics, INC. | $16.27 | 2019 | |
| Janssen Biotech, INC. | $13.46 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $13.19 | 2019 | |
| Clovis Oncology, INC. | $12.62 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ebenezer Berko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.